Dupilumab, a monoclonal antibody blocking the IL‐4/IL‐13 receptor component IL‐4Rα, has been recently approved for the treatment of various type‐2 inflammatory diseases including moderate‐to‐severe atopic dermatitis (AD), chronic rhinosinusitis and moderate‐to‐severe asthma.5, 6. Here, IL4R is linked to Alzheimer disease.